Murine renal cell carcinoma: Evaluation of a dendritic-cell tumour vaccine

BJU International

Volumn 88, Issue 4, 2001, Pages 418-424

  Chagnon, F ^a   Thompson Snipes, L ^a   Elhilali, M ^a   Tanguay, S ^a  

^a MGH Research Institute   (Canada)

Author keywords

Dendritic cell; Immune inhibition; Immunotherapy; Renal cell carcinoma; Renca; Tumour immunity; Tumour vaccine

Indexed keywords

CELL EXTRACT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER INHIBITION; CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC STEM CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; CANCER VACCINES; CARCINOMA, RENAL CELL; DENDRITIC CELLS; FLOW CYTOMETRY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C;

EID: 0035693527     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.02255.x     Document Type: Article

References (29)

1. Global cancer statistics
2. Prognostic factors in renal cancer
3. Renal cell carcinoma: Recent progress and future directions
4. Multicenter, randomized, phase III trial of CD8 (+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma
5. Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma
6. Dendritic cell based tumor vaccines
7. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-AO2Ol-specific peptides from prostate-specific membrane antigen
8. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
9. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
10. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
11. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
12. Experimental animal models for the study of therapeutic approaches in renal cell carcinoma
13. Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources
14. Immunosuppression in murine renal cell carcinoma. II. Identification of responsible lymphoid cell phenotypes and examination of elimination of suppression
15. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
16. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma
17. Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model
18. IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells
19. Interleukin-12 as an adjuvant for cancer immunotherapy
20. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
21. Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution
22. The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus
23. Renal cell carcinomaderived gangliosides suppress nuclear factor- kappaB activation in T cells
24. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
25. Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalpha
26. Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy
27. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses
28. Renal cell carcinoma metastatic to the lung: Potential benefit in the combination of biological therapy and surgery
29. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells